跳轉至內容
Merck
  • Autophagy activation and protection from mitochondrial dysfunction in human chondrocytes.

Autophagy activation and protection from mitochondrial dysfunction in human chondrocytes.

Arthritis & rheumatology (Hoboken, N.J.) (2015-01-22)
Paloma López de Figueroa, Martin K Lotz, Francisco J Blanco, Beatriz Caramés
摘要

Autophagy is a key pathway of cellular homeostasis for removing damaged macromolecules and organelles, including mitochondria. Recent studies indicate that activation of autophagy is defective in aging and osteoarthritis (OA), contributing to cell death and tissue damage. In addition, there is increasing evidence that mitochondrial dysfunction plays an important role in OA pathogenesis. The objective of this study was to determine whether activation of autophagy protects against mitochondrial dysfunction in human chondrocytes. Human chondrocytes were treated with oligomycin, an inhibitor of mitochondrial respiratory chain complex V. Autophagy activation was analyzed by determination of light chain 3 membrane-bound form II (LC3-II), a marker of autophagosome formation. To investigate whether autophagy protects from mitochondrial dysfunction, autophagy was induced by rapamycin, the selective inhibitor of mammalian target of rapamycin complex 1 (mTORC-1), and by torin 1, the inhibitor of mTORC-1 and mTORC-2. Small interfering autophagy-related 5 was used to evaluate the role of autophagy in mitochondrial dysfunction. Mitochondrial dysfunction was induced by treatment with oligomycin, which significantly decreased mitochondrial membrane potential (ΔΨm). This was associated with increased production of reactive oxygen species and cell death. Autophagy activation, as reflected by LC3-II, was decreased in a time-dependent manner. To evaluate whether autophagy regulates mitochondrial function, chondrocytes were pretreated with rapamycin and torin 1 before oligomycin. Autophagy activation significantly protected against mitochondrial dysfunction. Conversely, genetic inhibition of autophagy induced significant mitochondrial function defects. Our data highlight the role of autophagy as a critical protective mechanism against mitochondrial dysfunction. Pharmacologic interventions that enhance autophagy may have chondroprotective activity in cartilage degenerative processes such as OA.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
过氧化氢 溶液, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
过氧化氢 溶液, 50 wt. % in H2O, stabilized
Sigma-Aldrich
碘化丙啶, ≥94.0% (HPLC)
Sigma-Aldrich
过氧化氢溶液, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Sigma-Aldrich
放线菌素D, from Streptomyces sp., ~98% (HPLC)
Sigma-Aldrich
抗 α-微管蛋白单克隆抗体 小鼠抗, clone DM1A, ascites fluid
Sigma-Aldrich
放线菌素D, from Streptomyces sp., suitable for cell culture, ≥95%
Sigma-Aldrich
过氧化氢 溶液, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, purum p.a., ≥35% (RT)
Sigma-Aldrich
缬氨霉素, ≥98% (TLC), ≥90% (HPLC)
Sigma-Aldrich
雷帕霉素, Ready Made Solution, 2.5 mg/mL in DMSO (2.74 mM), from Streptomyces hygroscopicus
Sigma-Aldrich
JC-1, powder or solid (Crystals)
Millipore
过氧化氢 溶液, 3%, suitable for microbiology
Sigma-Aldrich
放线菌素D, from Streptomyces sp., ≥95% (HPLC)
Sigma-Aldrich
缬氨霉素, ≥99.0% (TLC)
Sigma-Aldrich
过氧化氢 溶液, 34.5-36.5%
Supelco
过氧化氢 溶液, ≥30%, for trace analysis
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
碘化丙啶 溶液
Sigma-Aldrich
缬氨霉素, Ready Made Solution, ~1 mg/mL in DMSO
Supelco
过氧化氢 溶液, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
碘化丙啶, ≥94% (HPLC)
Sigma-Aldrich
过氧化氢 溶液, tested according to Ph. Eur.
Supelco
钾离子载体 I, Selectophore, function tested
Supelco
Rapamycin, VETRANAL®, analytical standard
Sigma-Aldrich
过氧化氢 溶液, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis